NCT07053904View on ClinicalTrials.gov

Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Advanced Solid Tumors
Interventions
DRUG

Sequential use of P1101 and P1801

Sequential use of ropeginterferon alfa-2b and P1801 (anti PD-1 antibody drug)

Trial Locations (2)

110

Taipei Medical University Hospital, Taipei

23561

Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City

Sponsors

Lead Sponsor

PharmaEssentia
All Listed Sponsors
collaborator

Efficient Pharma Management Corp.

INDUSTRY

lead

PharmaEssentia

INDUSTRY

NCT07053904 - Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter